Avance Clinical to Showcase Clinical Excellence at World Orphan Drug Conference in Boston, April 23-25

Avance Clinical, the award-winning North American- and Australian market-leading CRO (contract research organization) for biotechs, will attend World Orphan Drug Conference in Boston (April 23-25, 2024) to share its rare diseases drug development expertise with biotechs (booth #730). Avance Clinical CEO Yvonne Lungershausen said that Avance Clinical is dedicated to advancing research and ensuring faster access to therapies that can make a significant difference in patients’ lives. “Avance Clinical has deep therapeutic knowledge of this area, completing over 50 trials in rare and orphan diseases globally in the last five years, including Fragile X syndrome, Duchenne Muscular Dystrophy, Rett syndrome, and erythropoietic protoporphyria,” she said. 

Login Or Register To Read Full Story